TransCon CNP for achondroplasia, a growth disorder and the most common type of dwarfism

Achieve regulatory approval for at least two of these products between 2020 and 2024

Identify a new rare disease therapeutic area with high-value product opportunities

Leverage our pipeline to create a leading integrated commercial business primarily focused on the U.S. market, with best-in-class rare disease products that address unmet needs

TransCon Technology

At the core of our strategic Vision 20/20 is our proprietary TransCon technology. This technology is designed to solve the fundamental limitations of previous approaches applied to extend duration of a drug’s action in the body, and to enhance the overall benefit of a given therapeutic. Learn More